Top

Osteoporosis International

Published in:

01-03-2014 | Original Article

Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients

Authors: J. L. Casado, S. Bañon, R. Andrés, M. J. Perez-Elías, A. Moreno, S. Moreno

Published in: Osteoporosis International | Issue 3/2014

Abstract

Summary

Eighty-one percent of human immunodeficiency virus (HIV)-infected patients had one or more of seven evaluated causes of secondary osteoporosis, and this rate increases with age. The type and number of causes were associated with a lower bone mineral density (BMD), and with an increased rate of osteopenia/osteoporosis, regardless of age and body mass index.

Introduction

The objective of this study was to determine whether factors of secondary osteoporosis were associated with lower BMD in HIV.

Methods

This was a cross-sectional study of 285 HIV-infected patients (25 % females) evaluating the impact of seven different factors of reduced BMD: hyperthyroidism, diabetes, chronic viral hepatitis, chronic kidney disease (CKD), hypovitaminosis D, secondary hyperparathyroidism, and hypogonadism. Dual-energy X-ray absorptiometry scan of the femoral neck was obtained at the clinical visit.

Results

Mean age was 45.7 years; osteopenia and osteoporosis were diagnosed in 38 and 6 %, respectively. Overall, 230 patients (81 %) had secondary factors; 107 (38 %) had only 1 cause, 94 (33 %) had 2, and 28 (10 %) had 3 or more, predominantly vitamin D deficiency in 61 %, hepatitis C virus coinfection in 45 %, and secondary hyperparathyroidism in 27 %. The number of secondary factors was closely related to a lower BMD, which is statistically significant for patients having ≥2 causes (0.77 vs 0.73 g/cm², p = 0.02). The rate of osteopenia ranged from 36 % without any cause to 57 % with three or more, osteoporosis from 0 to 19 %, and Z-score <−2 SD from 0 to 27 %, respectively. In a multivariate linear regression, adjusting by age, body mass index, and HIV-related factors, the number of secondary factors was independently associated with a lower BMD (ß coefficient −0.134; p = 0.02), mainly due to patients with hepatitis C virus (HCV) coinfection, secondary hyperparathyroidism, and CKD.

Conclusions

A high prevalence of secondary causes of osteoporosis is observed in HIV-infected patients, and its type and cumulative number determine a lower BMD, after adjusting by age and body mass index.

Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, Francioli P, D'Arminio Monforte A, Fox Z, Lundgren JD, EuroSIDA study group (2002) Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 16:1663–1671PubMedCrossRef

Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, Yarasheski KE (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14:F63–F67PubMedCentralPubMedCrossRef

Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE (2006) HIV infection and bone mineral density in middle aged women. Clin Infect Dis 42:1014–1020PubMedCrossRef

Jones S, Restrepo D, Kasowitz A, Korenstein D, Wallenstein S, Schneider A, Keller MJ (2008) Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int 19:913–918PubMedCrossRef

Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S (2004) Reduced bone density in HIV-infected women. AIDS 18:475–483PubMedCrossRef

Brown TT, Qaqish RB (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20:2165–2174PubMedCrossRef

Triant VA, Brown TT, Lee H, Grinspoon SK (2008) Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 93:3499–3504PubMedCrossRef

Young B, Dao CN, Buchacz K, Baker R, Brooks JT (2011) Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis 52:1061–1068PubMedCrossRef

Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA (2009) Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 51:554–561PubMedCrossRef

10.

Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D; ANRS 121 Hippocampe study group (2009) Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 23:817–824

11.

Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, Hoffmann M, Tebas P (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36:482–490PubMedCrossRef

12.

Inaba M (2004) Secondary osteoporosis: thyrotoxicosis, rheumatoid arthritis, and diabetes mellitus. J Bone Miner Metab 22:287–292PubMedCrossRef

13.

Crum NF, Furtek KJ, Olson PE, Amling CL, Wallace MR (2005) A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post- HAART eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDs 19:655–671PubMedCrossRef

14.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1–S130

15.

Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936PubMedCrossRef

16.

Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, Downs RW Jr; International Society for Clinical Densitometry (2004) Official positions of the International Society for Clinical Densitometry. J Clin Endocrinol Metab 89:3651–3655CrossRef

17.

World Health Organization (2007) Assessment of osteoporosis at the primary health care level. WHO, Geneva. www.who.int/chp/topics/rheumatic/en/index.html. Accessed May 2013

18.

Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ III, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467–475PubMedCrossRef

19.

Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM (1993) Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 341: 72–75

20.

Edwards BJ, Langman CB, Bunta AD, Vicuna M, Favus M (2008) Secondary contributors to bone loss in osteoporosis related hip fractures. Osteoporos Int 19:991–999PubMedCrossRef

21.

Deutschmann HA, Weger M, Weger W, Kotanko P, Deutschmann MJ, Skrabal F (2002) Search for occult secondary osteoporosis: impact of identified possible risk factors on bone mineral density. J Intern Med 252:389–397PubMedCrossRef

22.

Johnson BE, Lucasey B, Robinson RG, Lukert BP (1989) Contributing diagnoses in osteoporosis. The value of a complete medical evaluation. Arch Intern Med 149:1069–1072PubMedCrossRef

23.

Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, Luckey M (2002) Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87:4431–4437PubMedCrossRef

24.

Bours SPG, van Geel TA, Geusens P, Janssen MJ, Janzing HM, Hoffland GA, Willems PC, van den Bergh JP (2011) Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a clinical fracture. J Clin Endocrinol Metab 96:1360–1367PubMedCrossRef

25.

Khosla S, Amin S, Orwoll E (2008) Osteoporosis in men. Endocr Rev 29:441–464PubMedCrossRef

26.

Bolland MJ, Grey AB, Gamble GD, Reid IR (2007) Clinical review: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab 92:4522–4528PubMedCrossRef

27.

Chew NS, Doran PP, Powderly WG (2007) Osteopenia and osteoporosis in HIV: pathogenesis and treatment. Curr Opin HIV AIDS 2:318–323PubMedCrossRef

28.

Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Eisman JA, McCloskey EV, Mellstrom D, Melton LJ 3rd, Pols HA, Reeve J, Silman AJ, Tenenhouse A (2004) A family history of fracture and fracture risk: a meta-analysis. Bone 35:1029–1037PubMedCrossRef

29.

Ramayo E, Gonzalez-Moreno MP, Macias J, Cruz-Ruíz M, Mira JA, Villar-Rueda AM, García-García JA, Gómez-Mateos JM, Lozano F, Pineda JA (2005) Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy. AIDS Res Hum Retrovir 21:915–921PubMedCrossRef

30.

Liu H, Paige NM, Goldzweig CL, Wong E, Zhou A, Suttorp MJ, Munjas B, Orwoll E, Shekelle P (2008) Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline. Ann Intern Med 148:685–701PubMedCrossRef

31.

Rouillard S, Lane NE (2001) Hepatic osteodystrophy. Hepatology 33:301–307PubMedCrossRef

32.

Lin JC, Hsieh TY, Wu CC, Chen PJ, Chueh TH, Chang WK, Chu HC (2012) Association between chronic hepatitis C virus infection and bone mineral density. Calcif Tissue Int 91:423–429PubMedCrossRef

33.

Lo Re V, Guaraldi G, Leonard MD, Localio AR, Lin J, Orlando G, Zirilli L, Rochira V, Kostman JR, Tebas P (2009) Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. AIDS 23:2191–2198PubMedCentralPubMedCrossRef

34.

McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE (2011) Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224 s, a substudy of ACTG A5202. J Infect Dis 203:1791–1801PubMedCrossRef

35.

Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, Thompson M, Grant R, Pathak S, O'Hara B, Gvetadze R, Chillag K, Grohskopf L, Buchbinder SP (2011) Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PloS One 6:e23688. doi:10.1371/journal.pone.0023688 PubMedCentralPubMedCrossRef

36.

Isidro ML, Ruano B (2010) Bone disease in diabetes. Curr Diabetes Rev 6:144–155PubMedCrossRef

37.

Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, Yu Q, Zillikens MC, Gao X, Rivadeneira F (2012) Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol 27:319–332PubMedCentralPubMedCrossRef

38.

Sta RM, Li-Yu JT (2007) Investigation of the relationship between type 2 diabetes and osteoporosis using Bayesian inference. J Clin Densitom 10:386–390CrossRef

39.

The Endocrine Society. Summary from the 2nd Annual Andropause Consensus Meeting (Chevy Chase, MD): The Endocrine Society Continuing Medical Education Services, 2001

40.

Teichmann J, Lange U, Discher T, Lohmeyer J, Stracke H, Bretzel RG (2009) Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly active antiretrovial therapy. Eur J Med Res 14:59–64PubMedCentralPubMedCrossRef

41.

Grinspoon S (2005) Androgen deficiency and HIV infection. Clin Infect Dis 41:1804–1805PubMedCrossRef

42.

Nickolas TL, Leonard MB, Shane E (2008) Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74:721–731PubMedCrossRef

Title: Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients
Authors: J. L. Casado
S. Bañon
R. Andrés
M. J. Perez-Elías
A. Moreno
S. Moreno
Publication date: 01-03-2014
Publisher: Springer London
Published in: Osteoporosis International / Issue 3/2014
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-013-2506-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2014

Vertebral deformities and fractures are associated with MRI and pQCT measures obtained at the distal tibia and radius of postmenopausal women

Regional depth-specific subchondral bone density measures in osteoarthritic and normal patellae: in vivo precision and preliminary comparisons

Relative influence of heritability, environment and genetics on serum sclerostin

Relations of osteoporosis and follow-up duration to recurrent falls in older men and women

Bone mineral and stiffness loss at the distal femur and proximal tibia in acute spinal cord injury

Prevalence and progression of radiographic ossification of the posterior longitudinal ligament and associated factors in the Japanese population: a 3-year follow-up of the ROAD study